Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Data on 53 patients treated with remdesivir through the compassionate use program is published in New England Journal of Medicine.- Gilead Sciences

Written by | 12 Apr 2020

Gilead Sciences, Inc. announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVID-19 who were treated with the investigational antiviral remdesivir on an… read more.

Alnylam completes rolling submission of NDA to the FDA and submits MAA to the European Medicines Agency for lumasiran for the treatment of primary hyperoxaluria Type 1.

Written by | 8 Apr 2020

Alnylam Pharmaceuticals, Inc. announced the completion of the rolling submission of a New Drug Application (NDA) to the FDA for lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase… read more.

Phase III FALCON study of bardoxolone in patients with autosomal dominant polycystic kidney disease is paused.- Reata Pharma

Written by | 6 Apr 2020

Reata Pharmaceuticals, Inc. provided an update on the impact of the COVID-19 pandemic on its clinical programs, drug supply chain, and business operations The Company announced measures it… read more.

Retrospective study of Velphoro in Hyperphosphataemia published in Kidney Medicine journal.- Fresenius Medical

Written by | 2 Apr 2020

A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro (sucroferric oxyhydroxide chewable tablets), from Fresenius Medical, achieved target… read more.

DAPA-CKD trial for Farxiga is stopped early in patients with chronic kidney disease due to overwhelming efficacy.- AstraZeneca

Written by | 1 Apr 2020

The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped… read more.

Farxiga phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease.-AstraZeneca

Written by | 31 Mar 2020

The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped… read more.

Phase IV trial data with Rayaldee shows efficacy in chronic kidney disease.- OPKO Health

Written by | 27 Mar 2020

OPKO Health reported interim results from an ongoing Phase IV clinical trial comparing Rayaldee with three common treatment regimens for secondary hyperparathyroidism (SHPT) in adult patients with stage… read more.

Oncology Venture reports results of FDA meeting for dovitinib as a treatment for renal cell carcinoma.

Written by | 25 Mar 2020

Oncology Venture has had a meeting with the FDA to discuss a potential path to approval for dovitinib used to treat Renal Cell Carcinoma (RCC) (kidney cancer), the… read more.

Molecular traffic jam may underlie rare kidney disease, other protein misfolding disorders

Written by | 17 Nov 2019

Researchers find that several genetic disorders, including MUC1 kidney disease, may share a novel molecular mechanism — and identify a promising therapeutic lead. Misfolded MUC1-fs protein (green) builds up in the kidneys of a mouse model of MUC1 kidney disease.

Diabetes medication shows potential to reduce heart disease

Written by | 17 Nov 2019

A new study from St. Michael’s Hospital in Toronto, Canada shed lights on how a class of medications that help regulate blood sugar for patients with Type 2… read more.

Taking hypertensive medication at night is better

Written by | 16 Nov 2019

People with high blood pressure who take all their anti-hypertensive medication in one go at bedtime have better controlled blood pressure and a significantly lower risk of death… read more.

Kidney-resident macrophages — a role for healing during acute kidney injury?

Written by | 29 Oct 2019

These kidney macrophages reprogram to a developmental state after kidney injury, similar to those in newborn mice.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.